Jenny Agnes Greig;Anna P. Tretiakova;James M. Wilson
发明人:
James M. Wilson,Anna P. Tretiakova,Jenny Agnes Greig
申请号：
US13247306
公开号：
US20120058102A1
申请日:
2011.09.28
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent； e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.
